Health Effects of Oats and Oat Bioactive in Human
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03830736 |
Recruitment Status :
Completed
First Posted : February 5, 2019
Last Update Posted : May 1, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Postprandial Glucose Regulation | Combination Product: Oat Beverage 1 Combination Product: Oat Beverage 2 Combination Product: Oat Beverage 3 Combination Product: Oat Beverage 4 Combination Product: Control product | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 24 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Intervention Model Description: | a randomized blinded cross-over study |
Masking: | Single (Participant) |
Primary Purpose: | Prevention |
Official Title: | Effects of Oat and Oat Components on Cardiometabolic- and Cognitive Test Variables |
Actual Study Start Date : | February 18, 2019 |
Actual Primary Completion Date : | May 30, 2019 |
Actual Study Completion Date : | December 30, 2019 |
Arm | Intervention/treatment |
---|---|
Placebo Comparator: Control product
A glucose solution (glucose and water) based on 42 gram carbohydrates.
|
Combination Product: Control product
Glucose based beverage without added test components is used as control product |
Experimental: Oat Beverage 1
The test product is an oat based beverage with added vegetable oil. The test portion is based on 42 gram available carbohydrates and consumed as a breakfast meal prior to determinations of test variables in the morning.
|
Combination Product: Oat Beverage 1
Oat based beverage with added different concentration of extracted oat component. |
Experimental: Oat Beverage 2
The test product is an oat based beverage with added vegetable oil. The test portion is based on 42 gram available carbohydrates and consumed as a breakfast meal prior to determinations of test variables in the morning.
|
Combination Product: Oat Beverage 2
Oat based beverage with added different concentration of extracted oat component. |
Experimental: Oat Beverage 3
The test product is an oat based beverage with added vegetable oil. The test portion is based on 42 gram available carbohydrates and consumed as a breakfast meal prior to determinations of test variables in the morning.
|
Combination Product: Oat Beverage 3
Oat based beverage with added different concentration of extracted oat component. |
Experimental: Oat Beverage 4
The test product is an oat based beverage. The test portion is based on 42 gram available carbohydrates and consumed as a breakfast meal prior to determinations of test variables in the morning.
|
Combination Product: Oat Beverage 4
Oat based beverage with added different concentration of extracted oat component. |
- Blood glucose regulation [ Time Frame: 0 - 5.5 hours ( at fasting and then repeatedly after breakfast and Standardize lunch) ]Postprandial blood glucose regulation (incremental area under the curve) acute after intake of the test products and at forthcoming meals within 5.5 hours after consumption of test products.
- Serum insulin [ Time Frame: 0 - 5.5 hours ( at fasting and then repeatedly after breakfast and Standardize lunch) ]Acute effects of postprandial serum insulin concentrations (incremental area under the curve) after intake of the test products.
- plasma GLP-1 (glucagon-like peptide-1 ) [ Time Frame: 0 - 5.5 hours ( at fasting and then repeatedly after breakfast and Standardize lunch) ]Gastro-intestinale hormones involved in appetite and metabolic regulation
- IL (interleukin)-6 [ Time Frame: 0 - 5.5 hours ( at fasting and then repeatedly after breakfast and Standardize lunch) ]Inflammatory markers in blood
- Plasma PYY (peptide tyrosine tyrosine) [ Time Frame: 0 - 5.5 hours ( at fasting and then repeatedly after breakfast and Standardize lunch) ]Gastro-intestinale hormones involved in appetite and metabolic regulation
- IL- 1beta [ Time Frame: 0 - 5.5 hours ( at fasting and then repeatedly after breakfast and Standardize lunch) ]Inflammatory markers in blood
- Subjective appetite sensations [ Time Frame: 0 - 5.5 hours ( at fasting and then repeatedly after breakfast and Standardize lunch) ]Determined with VAS (visual analogue scale) scales (0-100 mm) as a range of subjective sensations related to appetite (such as hunger, desire to eat or fullness)
- Breath hydrogen concentrations [ Time Frame: 0 - 5.5 hours ( at fasting and then repeatedly after breakfast and Standardize lunch) ]Indicator of gut fermentation
- Mood (valence and activity) [ Time Frame: 0 - 5.5 hours ( at fasting and then repeatedly after breakfast and Standardize lunch) ]Determined with VAS (visual analogue scale) scales 0-100 mm

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 20 Years to 40 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- healthy adults
- BMI 18,5 - 25
- non smokers
- consuming a non-vegetarian diet that follows the Nordic guidances
Exclusion Criteria:
- Fasting blood glucose concentration >6.1 mmol/l
- known cardio-metabolic disease (e.g. diabetes, hypertension, metabolic syndrome), gastro-intestinal disorders such as IBS (irritable bowel syndrome) that can interfere with the study results, food allergies. Further no antibiotics or probiotics should have been consumed within 4 weeks prior to and during the study.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03830736
Sweden | |
Food Technology, engineering and Nutrition, LTH, Lund University | |
Lund, Sweden, 22100 |
Study Chair: | Anne Nilsson | Lund University |
Responsible Party: | Anne Nilsson, Associate professor, Lund University |
ClinicalTrials.gov Identifier: | NCT03830736 |
Other Study ID Numbers: |
Protokoll 2018/8 |
First Posted: | February 5, 2019 Key Record Dates |
Last Update Posted: | May 1, 2020 |
Last Verified: | April 2020 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |